Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus.
暂无分享,去创建一个
A. Joly | S. Twigg | R. Rosenfeld | Y. Oh | Ho-Seong Kim | Michelle M. Chen | H. Kim | J. Tsubaki | M. M. Chen | S. Chakrapani | Michelle M. Chen | Ron G. Rosenfeld | S. Chakrapani
[1] Y. Kaneda,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.
[2] M. Brownlee,et al. Negative consequences of glycation. , 2000, Metabolism: clinical and experimental.
[3] R. Bucala,et al. Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts. , 2000, Bioconjugate chemistry.
[4] J. Yee,et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. , 2000, Journal of the American Society of Nephrology : JASN.
[5] T. Kislinger,et al. N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.
[6] Gary R. Grotendorst,et al. Connective tissue growth factor mediates transforming growth factor b-induced collagen synthesis : down-regulation by cAMP , 1999 .
[7] H. Friess,et al. Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. , 1999, Annals of surgery.
[8] R. G. Paul,et al. The effect of advanced glycation end-product formation upon cell-matrix interactions. , 1999, The international journal of biochemistry & cell biology.
[9] G. King,et al. Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. , 1999, Diabetes care.
[10] L. Lau,et al. Fisp12/Mouse Connective Tissue Growth Factor Mediates Endothelial Cell Adhesion and Migration through Integrin αvβ3, Promotes Endothelial Cell Survival, and Induces Angiogenesis In Vivo , 1999, Molecular and Cellular Biology.
[11] F. Cuccurullo,et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. , 1999, The Journal of pediatrics.
[12] A. Schmidt,et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.
[13] F. Martin,et al. Suppression Subtractive Hybridization Identifies High Glucose Levels as a Stimulus for Expression of Connective Tissue Growth Factor and Other Genes in Human Mesangial Cells* , 1999, The Journal of Biological Chemistry.
[14] Paul J Thornalley. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. , 1998, Cellular and molecular biology.
[15] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[16] Gary R. Grotendorst,et al. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? , 1998, The international journal of biochemistry & cell biology.
[17] M. Brauchle,et al. Dexamethasone Is a Novel Potent Inducer of Connective Tissue Growth Factor Expression , 1998, The Journal of Biological Chemistry.
[18] E. Wilson,et al. Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells. , 1998, The Journal of clinical endocrinology and metabolism.
[19] A. Schmidt,et al. Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes. , 1998, Annals of periodontology.
[20] M. Takigawa,et al. Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. , 1998, Journal of biochemistry.
[21] R. O. Stuart,et al. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. , 1998, Kidney international.
[22] R. Bende,et al. Expression of connective tissue growth factor in human renal fibrosis. , 1998, Kidney international.
[23] R. Bucala,et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. , 1998, The Journal of clinical investigation.
[24] R. Ziegler,et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.
[25] P. A. Harding,et al. Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. , 1998, Growth factors.
[26] S. Mohan,et al. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. , 1998, Endocrinology.
[27] N. Nakamura,et al. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. , 1997, Biochemical and biophysical research communications.
[28] E. Wilson,et al. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[29] K. Swisshelm,et al. Developmental regulation of Mac25/insulin-like growth factor-binding protein-7 expression in skeletal myogenesis. , 1997, Experimental cell research.
[30] G. Romeo,et al. Upregulation of Mesangial Growth Factor and Extracellular Matrix Synthesis by Advanced Glycation End Products Via a Receptor-Mediated Mechanism , 1997, Diabetes.
[31] T. Luther,et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. , 1997, Circulation.
[32] Gary R. Grotendorst. Connective tissue growth factor: a mediator of TGF-β action on fibroblasts , 1997 .
[33] A. Schmidt,et al. Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.
[34] R. Bucala,et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[35] Hiroshi Yamamoto,et al. Advanced Glycation End Products-driven Angiogenesis in Vitro , 1997, The Journal of Biological Chemistry.
[36] A. Schmidt,et al. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose , 1997, European journal of clinical investigation.
[37] W. März,et al. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. , 1997, Circulation.
[38] P. Riederer,et al. Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[39] Gary R. Grotendorst,et al. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. , 1996, The Journal of investigative dermatology.
[40] Gary R. Grotendorst,et al. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[41] G. Striker,et al. Administration of AGEs in vivo induces extracellular matrix gene expression. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[42] Gary R. Grotendorst,et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. , 1995, The Journal of investigative dermatology.
[43] L. L. Moore,et al. Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes , 1995, Diabetes.
[44] M. Cybulsky,et al. Advanced Glycation Endproducts Promote Adhesion Molecule (VCAM-1, ICAM-1) Expression and Atheroma Formation in Normal Rabbits , 1995, Molecular medicine.
[45] A. Schmidt,et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[46] G. Striker,et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[47] Gary R. Grotendorst,et al. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. , 1993, Molecular biology of the cell.
[48] A. Huntley. Cutaneous manifestations of diabetes mellitus. , 1982, Diabetes/metabolism reviews.
[49] H. Vlassara,et al. Receptor-Mediated Interactions of Advanced Glycosylation End Products With Cellular Components Within Diabetic Tissues , 1992, Diabetes.
[50] V. Monnier,et al. Pentosidine Formation in Skin Correlates With Severity of Complications in Individuals With Long-Standing IDDM , 1992, Diabetes.
[51] R. Baxter,et al. Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. , 1992, Endocrinology.
[52] R. Bucala,et al. Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.
[53] C. Bombardier,et al. Pathologic features of diabetic thick skin. , 1987, Journal of the American Academy of Dermatology.
[54] A. Cerami,et al. Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. , 1986, Clinical chemistry.
[55] J. Seibold. Digital sclerosis in children with insulin-dependent diabetes mellitus. , 1982, Arthritis and rheumatism.